Captrust Financial Advisors Spring Works Therapeutics, Inc. Transaction History

Captrust Financial Advisors

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	BUY	$18.36 - $60.07 $477 - $1,561	26 Added 27.96%	119 $3,000
Q1 2022 May 16, 2022	SELL	$48.97 - $65.46 $3,232 - $4,320	-66 Reduced 41.51%	93 $5,000
Q4 2021 Feb 14, 2022	BUY	$53.3 - $75.84 $8,474 - $12,058	159 New	159 $10,000
Q3 2021 Nov 16, 2021	SELL	$62.66 - $88.26 $7,895 - $11,120	-126 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$67.45 - $85.63 $6,205 - $7,877	92 Added 270.59%	126 $10,000
Q1 2021 May 17, 2021	BUY	$65.1 - $93.59 $2,213 - $3,182	34 New	34 $3,000

238

69.8M

144K

257K

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.43B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.